Literature DB >> 7536953

Measurement of colony-stimulating factors in synovial fluid: potential clinical value.

A L Bell1, M K Magill, W R McKane, F Kirk, A E Irvine.   

Abstract

In this study, 100 synovial fluid (SF) samples from patients with a variety of arthritides were assayed for levels of colony-stimulating factors (CSFs) using a human bone-marrow bioassay and enzyme immunoassays for granulocyte (G-) and granulocyte-macrophage (GM-) CSFs. GM-CSF was found more frequently in samples from rheumatoid arthritis (RA) subjects (49%) than in non-RA samples (29%). Absence of GM- but not G- or bioassay CSFs characterised samples from subjects with psoriatic arthritis and ankylosing spondylitis (n = 14). There was strong evidence of an antagonistic relationship between levels of G- and GM-CSFs in samples from RA patients, an effect independent of drug treatment. However, treatment with non-steroidal anti-inflammatory agents (NSAIDs) may affect reported CSF concentrations: G-CSF levels were significantly lower in samples from subjects not taking NSAIDs. These results suggest that SF-CSF estimations using commercially available assays could provide useful diagnostic clues for clinicians, but careful interpretation is warranted particularly in patients on long-term NSAID treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536953     DOI: 10.1007/bf00262295

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

1.  Cytokine measurements in biological fluids.

Authors:  A P Cope; F M Brennan
Journal:  Br J Rheumatol       Date:  1992-11

2.  Colony stimulating factor occurs in both inflammatory and noninflammatory synovial fluids.

Authors:  J B Smith; M H Bocchieri; J B Smith; L Sherbin-Allen; J L Abruzzo
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes.

Authors:  J M Alvaro-Gracia; N J Zvaifler; G S Firestein
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

4.  Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes.

Authors:  D Chantry; M Turner; F Brennan; A Kingsbury; M Feldmann
Journal:  Cytokine       Date:  1990-01       Impact factor: 3.861

5.  Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha.

Authors:  J M Alvaro-Gracia; N J Zvaifler; C B Brown; K Kaushansky; G S Firestein
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

6.  The detection and initial characterization of colony-stimulating factors in synovial fluid.

Authors:  D J Williamson; C G Begley; M A Vadas; D Metcalf
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

7.  Human umbilical cord conditioned medium: a stimulus for human CFU-G.

Authors:  A E Irvine; T C Morris; H Kennedy; G B Wisdom; J M Bridges
Journal:  Exp Hematol       Date:  1984-01       Impact factor: 3.084

8.  Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha.

Authors:  C Haworth; F M Brennan; D Chantry; M Turner; R N Maini; M Feldmann
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

9.  Cytokine inter-relationships and their association with disease activity in arthritis.

Authors:  I Holt; R G Cooper; J Denton; A Meager; S J Hopkins
Journal:  Br J Rheumatol       Date:  1992-11

10.  Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis.

Authors:  G S Firestein; W D Xu; K Townsend; D Broide; J Alvaro-Gracia; A Glasebrook; N J Zvaifler
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  17 in total

1.  The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.

Authors:  Tohru Ikuta; Adekunle D Adekile; Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Betsy Clair; Abdullah Kutlar; Nadine Odo; C Alvin Head
Journal:  Blood Cells Mol Dis       Date:  2011-09-25       Impact factor: 3.039

Review 2.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

Review 3.  Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.

Authors:  Chiara Crotti; Elena Agape; Andrea Becciolini; Martina Biggioggero; Ennio Giulio Favalli
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

4.  Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid.

Authors:  A L Bell; M K Magill; R McKane; A E Irvine
Journal:  Ann Rheum Dis       Date:  1995-11       Impact factor: 19.103

Review 5.  [Pathogenic cells of rheumatic inflammation as the target of modern therapies].

Authors:  J R Kalden
Journal:  Z Rheumatol       Date:  2015-02       Impact factor: 1.372

6.  Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.

Authors:  Jamie Campbell; Josquin Nys; Laura Eghobamien; E Suzanne Cohen; Matthew J Robinson; Matthew A Sleeman
Journal:  MAbs       Date:  2016-08-12       Impact factor: 5.857

7.  Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis.

Authors:  R R Minter; E S Cohen; B Wang; M Liang; I Vainshtein; G Rees; L Eghobamien; P Harrison; D A Sims; C Matthews; T Wilkinson; P Monk; C Drinkwater; L Fabri; A Nash; M McCourt; L Jermutus; L Roskos; I K Anderson; M A Sleeman
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

8.  Activation of Fc gamma RI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses.

Authors:  Motoyuki Tanaka; Stephan R Krutzik; Peter A Sieling; Delphine J Lee; Thomas H Rea; Robert L Modlin
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

Review 9.  Emerging immunotherapies for rheumatoid arthritis.

Authors:  Gary Reynolds; Faye A H Cooles; John D Isaacs; Catharien M U Hilkens
Journal:  Hum Vaccin Immunother       Date:  2014-02-17       Impact factor: 3.452

10.  Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.

Authors:  Gerd R Burmester; Michael E Weinblatt; Iain B McInnes; Duncan Porter; Olga Barbarash; Mykola Vatutin; Istvan Szombati; Ehsanollah Esfandiari; Matthew A Sleeman; Christopher D Kane; Guy Cavet; Bing Wang; Alex Godwood; Fabio Magrini
Journal:  Ann Rheum Dis       Date:  2012-12-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.